ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "antiphospholipid syndrome"

  • Abstract Number: 0075 • ACR Convergence 2021

    Endothelial Cell-activating Antibodies in COVID-19

    Hui Shi1, Yu Zuo2, Sherwin Navaz2, Alyssa Harbaugh2, Claire Hoy2, Alex Gandhi2, Gautam Sule2, Srilakshmi Yalavarthi2, Kelsey Gockman2, Jacqueline Madison2, Jintao Wang2, Melanie zuo2, Yue Shi3, Michael Maile2, Yogendra Kanthi2 and Jason Knight2, 1Division of Rheumatology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, 2University of Michigan, Ann Arbor, MI, 3Shanghai Sports School, Shanghai, China (People's Republic)

    Background/Purpose: Patients with COVID-19 are at high risk for occlusion of vascular beds of all sizes. Considering endothelial cell activation has regularly been described as…
  • Abstract Number: 0076 • ACR Convergence 2021

    Predicting the Transitions Between Lupus Anticoagulant Status and Thrombosis in SLE Using a Multi-state Markov Model

    Selcan Demir1, Jessica Li2, Laurence Magder3 and Michelle Petri4, 1Hacettepe University Faculty of Medicine, Ankara, Turkey, 2Johns Hopkins University, Baltimore, MD, 3University of Maryland, Baltimore, Baltimore, MD, 4Johns Hopkins University School of Medicine, Baltimore, MD

    Background/Purpose: Antiphospholipid syndrome (APS) is a significant cause of morbidity and mortality in patients with SLE and lupus anticoagulant (LAC) positivity is the best predictor…
  • Abstract Number: 0077 • ACR Convergence 2021

    Association of Lupus Nephritis and Other Clinical Features with Antiphospholipid Antibody Positivity Among Patients with Systemic Lupus Erythematosus

    Prarthana Jain, Jim Oates, Dulaney Wilson and Diane Kamen, Medical University of South Carolina, Charleston, SC

    Background/Purpose: Antiphospholipid antibody (aPL) positivity is associated with elevated risk of thrombosis among patients with SLE, but other clinical associations are less well-known. The goal…
  • Abstract Number: 0078 • ACR Convergence 2021

    Frequency and Clinical Characteristics of Secondary Antiphospholipid Syndrome in Systemic Lupus Erythematosus: The Georgia Lupus Registry

    Jinan al-naqeeb1, Gaobin Bao2, Cristina Drenkard2 and S Sam Lim3, 1Emory University, Decatur, GA, 2Emory University, Atlanta, GA, 3Department of Medicine, Division of Rheumatology, Emory University School of Medicine, Atlanta, GA

    Background/Purpose: Although APS was originally described in those with SLE, the epidemiology and clinical characteristics of secondary APS (2APS) has not been well described in…
  • Abstract Number: 0079 • ACR Convergence 2021

    Association Between Preconception Complement Levels and Use of Hydroxychloroquine with Pregnancy Outcome in Patients with Primary Antiphospholipid Syndrome and Carriers of Antiphospholipid Antibodies: An International Multicenter Study

    Daniele Lini1, Cecilia Nalli2, Laura Andreoli3, Francesca Crisafulli1, Micaela Fredi1, Maria Grazia Lazzaroni1, Viktoria Bitsadze4, Antonia Calligaro5, Valentina Canti6, Roberto Caporali7, Francesco Carubbi8, Cecilia Chighizola9, Paola Conigliaro10, Fabrizio Conti11, Caterina De Carolis12, Teresa Del Ross5, Maria Favaro5, Maria Gerosa9, Annamaria Iuliano13, Jamilya Khizroeva4, Alexander Makatsariya4, Pier Luigi Meroni14, Marta Mosca15, Melissa Padovan16, Roberto Perricone10, Patrizia Rovere Querini6, Gian Domenico Sebastiani13, Chiara Tani17, Marta Tonello18, Simona Truglia11, Dina Zucchi15, Franco Franceschini1 and Angela Tincani19, 1Rheumatology and Clinical Immunology Unit, ASST Spedali Civili and University of Brescia, Brescia, Italy, 2ASST SPEDALI CIVILI DI BRESCIA, Brescia, Italy, 3University of Brescia, Brescia, Italy, 4Department of Obstetrics and Gynecology, I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University), Moscow, Russia, 5Rheumatology Unit, Department of Medicine, University of Padua, Padua, Italy, 6Division of Immunology, Transplantation and Infectious Diseases, IRCCS San Raffaele Scientific Institute, Milan, Italy, 7Policlinico S. Matteo University, Pavia, Italy, 8Department of Biotechnological and Applied Clinical Science, Rheumatology Unit, School of Medicine, University of L'Aquila, L'Aquila, Italy, 9University of Milan, Milan, Italy, 10Rheumatology, Allergology and Clinical Immunology, Department of "Medicina dei Sistemi", University of Rome Tor Vergata, Rome, Italy, 11Lupus Clinic, Reumatologia, Dipartimento di Scienze Cliniche Internistiche, Anestesiologiche e Cardiovascolari, Sapienza Università di Roma, Rome, Italy, 12Polymedical Center for Prevention of Recurrent Spontaneous Abortion, Rome, Italy, 13Rheumatology Unit, Azienda Ospedaliera San Camillo-Forlanini, Rome, Italy, 14Division of Rheumatology, ASST.G Pini, Department of Clinical Sciences and Community Health, University of Milan and Istituto Auxologico Italiano, Milan, Italy, 15Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy, 16Rheumatology Unit, Department of Medical Sciences, University of Ferrara and Azienda Ospedaliero-Universitaria S. Anna, Ferrara, Italy, 17Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy, 18BSC, Rheumatology Unit, Department of Medicine, University of Padua, Padua, Italy, 19ASST Spedali Civili-University of Brescia, Gussago, Italy

    Background/Purpose: APS is a rare autoimmune disease characterized by thrombotic events and/or pregnancy morbidities in the presence of confirmed positivity for aPL. Complement was demonstrated…
  • Abstract Number: 0080 • ACR Convergence 2021

    One Point Increase in the Initial Damage as Measured by the Damage Index for Antiphospholipid Syndrome Predicts Mortality in a Multi-Ethnic Group of Thrombotic Antiphospholipid Syndrome Patients

    Pedro Gaspar1, Filipa Farinha2, Zara Sayar3, Maria Efthymiou,4, Hannah Cohen3 and David Isenberg2, 1Department of Internal Medicine 2, University Hospital of Santa Maria, Lisbon, Portugal, 2Centre for Rheumatology, University College London, London, United Kingdom, 3Department of Haematology, University College London Hospitals NHS Foundation Trust, London, United Kingdom, 4Haemostasis Research Unit, Department of Haematology, University College London, London, United Kingdom

    Background/Purpose: The chronic and recurrent nature of antiphospholipid syndrome (APS) leads to damage accrual that impairs long-term functional status and survival. The Damage Index for…
  • Abstract Number: 0081 • ACR Convergence 2021

    Thrombin Generation Assay and Lupus Anticoagulant Identify Different Populations of Patients with Antiphospholipid Antibodies

    Massimo Radin1, Alice Barinotti1, Irene Cecchi2, Silvia Grazietta Foddai1, Elena Rubini1, Dario Roccatello1, Elisa Menegatti1 and Savino Sciascia1, 1University of Turin, Turin, Italy, 2University of Turin, Torino, Italy

    Background/Purpose: Risk stratification in patients with antiphospholipid antibodies (aPL) remains a clinical challenge. We aim to evaluate the role of Thrombin Generation Assay (TGA) in…
  • Abstract Number: 0082 • ACR Convergence 2021

    Association of Current Cigarette Smoking and Obesity with Antiphospholipid Antibodies and Thrombosis in 1216 International Patients Evaluated for Suspected Antiphospholipid Syndrome (APS)

    Medha Barbhaiya1, Deanna Jannat-Khah1, Doruk Erkan1, Karen Costenbader2 and On Behalf of New APS Classification Criteria Development Case Collectors1, 1Hospital for Special Surgery, New York, NY, 2Brigham and Women's Hospital, Belmont, MA

    Background/Purpose: Few studies have evaluated the role of environmental factors in APS. While antiphospholipid antibodies (aPL) may be induced by environmental stiumuli, e.g., viruses, cardiovascular…
  • Abstract Number: 0083 • ACR Convergence 2021

    Cardiac Valve Surgery Outcomes in the Antiphospholipid Syndrome

    Tali Eviatar1, Stanley Niznik2, Nancy Agmon-Levin2 and Daphna Paran3, 1Tel Aviv Sourasky Medical Center, Givataim, Israel, 2Sheba Medical Center, Ramat Gan, Israel, 3Tel Aviv Sourasky Medical Center-Ichilov Hospital, Even Yehuda, Israel

    Background/Purpose: Cardiac valve involvement in the APS is prevalent, necessitating valve surgery in about 5% of the patients. Data regarding valve surgery outcomes in APS…
  • Abstract Number: 0948 • ACR Convergence 2021

    Immunometabolism of Neutrophils in Antiphospholipid Syndrome (APS)

    Ajay Tambralli1, Alyssa Harbaugh2, Shanea Estes2, Srilakshmi Yalavarthi2, Claire Hoy2, Gautam Sule2 and Jason Knight2, 1University of Michigan, Ypsilanti, MI, 2University of Michigan, Ann Arbor, MI

    Background/Purpose: Neutrophil hyperactivity and neutrophil extracellular trap (NET) release (NETosis) appear to play roles in APS pathophysiology. Until recently, it was thought that neutrophils relied…
  • Abstract Number: 0069 • ACR Convergence 2021

    First and Recurrent Thrombosis Risk After 3842 Patient-Years of Follow-Up: Prospective Results from AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository (

    Yasaman Ahmadzadeh1, Danieli Andrade2, Maria Tektonidou3, Vittorio Pengo4, Savino Sciascia5, Amaia Ugarte6, H. Michael Belmont7, Maria Gerosa8, Paul R Fortin9, Maria Angeles Aguirre10, Lanlan Ji11, Tatsuya Atsumi12, Hannah Cohen13, Guilherme Ramires de Jesus14, D. Ware Branch15, Angela Tincani16, Nina Kello17, Michelle Petri18, Esther Rodriguez-Almaraz19, Roberto Ríos-Garcés20, Yu Zuo21, Bahar Artim-Esen22, Rohan Willis23, Maria Laura Bertolaccini24, Robert Roubey25, Doruk Erkan1 and on Behalf of APS ACTION1, 1Hospital for Special Surgery, New York, NY, 2Hospital das Clinicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, 3FORZAFORTE HELLAS LTD, Athens, Greece, 4Padova University Hospital, Padova, Italy, 5University of Turin, Turin, Italy, 6Hospital Universitario Cruces, Barakaldo, Spain, 7NYU School of Medicine, New York, NY, 8University of Milan, Milan, Italy, 9CHU de Quebec - Universite Laval, Québec City, QC, Canada, 10IMIBIC/Reina Sofia Hospital/University of Córdoba, Córdoba, Spain, 11Peking University First Hospital, Beijing, China (People's Republic), 12Hokkaido University, Sapporo, Japan, 13Department of Haematology, University College London Hospitals NHS Foundation Trust, London, United Kingdom, 14Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil, 15University of Utah, Salt Lake City, UT, 16ASST Spedali Civili-University of Brescia, Gussago, Italy, 17Zucker School of Medicine at Hofstra/Northwell Health, Manhasset, NY, 18Johns Hopkins University School of Medicine, Baltimore, MD, 19Hospital Universitario 12 de Octubre, Madrid, Spain, 20Hospital Clínic de Barcelona, Barcelona, Spain, 21University of Michigan, Ann Arbor, MI, 22Istanbul University School of Medicine, İstanbul, Turkey, 23University of Texas Medical Branch, Galveston, TX, 24King's College London, London, United Kingdom, 25University of North Carolina, Chapel Hill, NC

    Background/Purpose: APS ACTION “Registry” was created to study the natural course of disease over 10 years in persistently antiphospholipid antibody (aPL)-positive patients with/without other systemic…
  • Abstract Number: 0949 • ACR Convergence 2021

    Single-Cell RNA Sequencing of APS Skin Reveals Endothelial Pathology and Cellular Interactions

    Hui Shi1, Allison Billi2, Rachael Wasikowski1, Claire Hoy3, Kelsey Gockman1, Lam Tsoi1, Johann Gudjonsson2, Pei-Suen Tsou1 and Jason Knight1, 1University of Michigan, Ann Arbor, MI, 2Department of Dermatology, University of Michigan, Ann Arbor, MI, 3University of Michigan, Ann Arbor

    Background/Purpose: Although antiphospholipid syndrome (APS) regularly presents with discrete thrombotic events, many patients will also acquire organ damage over time secondary to occlusive neointimal formation…
  • Abstract Number: 0070 • ACR Convergence 2021

    Pregnancy Outcomes of Antiphospholipid Antibody Positive Patients: Prospective Results from AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository (“Registry”)

    Zeynep Belce Erton1, Ecem Sevim2, Guilherme Ramires de Jesus3, Ricard Cervera4, Lanlan Ji5, Vittorio Pengo6, Amaia Ugarte7, Danieli Andrade8, Laura Andreoli9, Tatsuya Atsumi10, Paul R Fortin11, Maria Gerosa12, Yu Zuo13, Michelle Petri14, Savino Sciascia15, Maria Tektonidou16, Maria Angeles Aguirre17, D. Ware Branch18, Doruk Erkan1 and on Behalf of APS ACTION1, 1Hospital for Special Surgery, New York, NY, 2Montefiore Medical Center - Wakefield Campus, Bronx, NY, 3Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil, 4Hospital Clinic Barcelona, Barcelona, Spain, 5Peking University First Hospital, Beijing, China (People's Republic), 6Padova University Hospital, Padova, Italy, 7Hospital Universitario Cruces, Barakaldo, Spain, 8Hospital das Clinicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, 9University of Brescia, Brescia, Italy, 10Hokkaido University, Sapporo, Japan, 11CHU de Quebec - Universite Laval, Québec City, QC, Canada, 12University of Milan, Milan, Italy, 13University of Michigan, Ann Arbor, MI, 14Johns Hopkins University School of Medicine, Baltimore, MD, 15University of Turin, Turin, Italy, 16FORZAFORTE HELLAS LTD, Athens, Greece, 17IMIBIC/Reina Sofia Hospital/University of Córdoba, Córdoba, Spain, 18University of Utah, Salt Lake City, UT

    Background/Purpose: APS ACTION Registry was created to study the natural course of disease over 10 years in persistently antiphospholipid antibody (aPL) positive patients with or…
  • Abstract Number: 0950 • ACR Convergence 2021

    Mammalian Target of Rapamycin (mTOR) Pathway Assessment in Antiphospholipid Antibody Positive Patients with Livedo Reticularis/Racemosa

    Ecem Sevim1, Salma Siddique2, Madhavi Latha Chalasani3, Susan Chyou4, William Shipman3, Orla O`Shea5, Oral Alpan6, Stephane Zuily7, Joanna Harp8, Theresa Lu3 and Doruk Erkan3, 1Montefiore Medical Center - Wakefield Campus, Bronx, NY, 2Nemours/A.I.duPont Hospital for Children, Wilmington, DE, 3Hospital for Special Surgery, New York, NY, 4Autoimmunity and Inflammation Program, Hospital for Special Surgery, New York, NY, 5Analytical Microscopy Core Laboratory, Hospital for Special Surgery, New York, NY, 6O&O Alpan Medical Center, Vienna, VA, 7Nancy Academic Hospital, Vandoeuvre-ls-Nancy, France, 8Dermatology, Weill Cornell Medicine, New York, NY

    Background/Purpose: Endothelial proliferation is a key finding in antiphospholipid antibody (aPL)-positive patients with microvascular disease. The mTOR pathway plays a role in the endothelial proliferation…
  • Abstract Number: 0071 • ACR Convergence 2021

    Damage Accrual Measured by DIAPS in Antiphospholipid Antibody (aPL)-positive Patients: Results from AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository (“Registry”)

    Gustavo Balbi1, Yasaman Ahmadzadeh2, Maria Tektonidou3, Vittorio Pengo4, Savino Sciascia5, Amaia Ugarte6, H. Michael Belmont7, Maria Gerosa8, Paul R Fortin9, Chary lopez-pedrera10, Lanlan Ji11, Tatsuya Atsumi12, Hannah Cohen13, Guilherme Ramires de Jesus14, D. Ware Branch15, Cecilia Nalli16, Nina Kello17, Michelle Petri18, Esther Rodriguez-Almaraz19, Giuseppe Barilaro20, Jason Knight21, Bahar Artim-Esen22, Rohan Willis23, Maria Laura Bertolaccini24, Robert Roubey25, Doruk Erkan2, Danieli De Andrade1 and on Behalf of APS ACTION2, 1University of São Paulo, São Paulo, Brazil, 2Hospital for Special Surgery, New York, NY, 3FORZAFORTE HELLAS LTD, Athens, Greece, 4Padova University Hospital, Padova, Italy, 5University of Turin, Turin, Italy, 6Hospital Universitario Cruces, Barakaldo, Spain, 7NYU School of Medicine, New York, NY, 8University of Milan, Milan, Italy, 9CHU de Quebec - Universite Laval, Québec City, QC, Canada, 10IMIBIC/Reina Sofia Hospital/University of Córdoba, Córdoba, Spain, 11Peking University First Hospital, Beijing, China (People's Republic), 12Hokkaido University, Sapporo, Japan, 13Department of Haematology, University College London Hospitals NHS Foundation Trust, London, United Kingdom, 14Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil, 15University of Utah, Salt Lake City, UT, 16ASST SPEDALI CIVILI DI BRESCIA, Brescia, Italy, 17Zucker School of Medicine at Hofstra/Northwell Health, Manhasset, NY, 18Johns Hopkins University School of Medicine, Baltimore, MD, 19Hospital Universitario 12 de Octubre, Madrid, Spain, 20Clínic Barcelona - Hospital Universitari, Barcelona, Spain, 21University of Michigan, Ann Arbor, MI, 22Istanbul University School of Medicine, İstanbul, Turkey, 23University of Texas Medical Branch, Galveston, TX, 24King's College London, London, United Kingdom, 25University of North Carolina, Chapel Hill, NC

    Background/Purpose: Damage Index in APS (DIAPS) is a scoring system developed to assess long-term damage in thrombotic primary antiphospholipid syndrome (PAPS), which also correlates with…
  • « Previous Page
  • 1
  • …
  • 7
  • 8
  • 9
  • 10
  • 11
  • …
  • 19
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology